Iloprost reduces myocardial edema in a rat model of myocardial ischemia reperfusion

Basit Öğe Kaydı
dc.contributor.authorCaliskan, A.
dc.contributor.authorYavuz, C.
dc.contributor.authorKarahan, O.
dc.contributor.authorYazici, S.
dc.contributor.authorGuclu, O.
dc.contributor.authorDemirtas, S.
dc.contributor.authorMavitas, B.
dc.date.accessioned2024-04-24T17:14:34Z
dc.date.available2024-04-24T17:14:34Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: Myocardial ischemia severely reduces myocyte longevity and function. Extensive interstitial edema and cell damage occur as a result of myocardial reperfusion injury. Current therapies are directed at prevention of ischemia-induced damage to cardiac tissue. Iloprost is a novel pharmaceutical agent for the treatment of ischemia. Methods: Twenty rats were segregated into four experimental groups. The procedure control group consisted of four rats undergoing a sham operation. The remaining 16 rats were divided into two equal groups. The first group (control group) received a continuous intravenous infusion of physiological serum immediately prior to the procedure. Iloprost was administered by a continuous intravenous infusion into the right jugular vein at an infusion rate of 100 ng/kg/min for 30 minutes prior to reperfusion in the experimental group (study group). Following the infusion treatments, ligation of the left coronary artery was conducted for 30 minutes to induce myocardial ischemia. The rats were euthanized 24 hours after reperfusion and cardiac tissue was harvested from all specimens for analysis. Results: Histological examination revealed three myocardial tissue specimens with grade II damage and five myocardial tissue specimens with grade III reperfusion injury in the control group. However, the study group consisted of two grade III myocardial tissue specimens, five grade 11 myocardial tissue specimens and one grade 1 myocardial tissue specimen. Moreover, a statistically significant reduction in myocardial edema was observed in the study group (p=0.022). Conclusion: Our results support the hypothesis that iloprost enhances protection against cardiac ischemia reperfusion injury. This protective effect may be associated with vasodilation, antioxidant or anti-edema mechanisms.en_US
dc.identifier.doi10.1177/0267659113514472
dc.identifier.endpage264en_US
dc.identifier.issn0267-6591
dc.identifier.issn1477-111X
dc.identifier.issue3en_US
dc.identifier.pmid24297774
dc.identifier.scopus2-s2.0-84899057128
dc.identifier.scopusqualityQ1
dc.identifier.startpage260en_US
dc.identifier.urihttps://doi.org/10.1177/0267659113514472
dc.identifier.urihttps://hdl.handle.net/11468/18058
dc.identifier.volume29en_US
dc.identifier.wosWOS:000336186600011
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofPerfusion-Uk
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMyocardial Ischemiaen_US
dc.subjectReperfusionen_US
dc.subjectIloprosten_US
dc.subjectAnti-Edema Efficacyen_US
dc.subjectCardioprotectionen_US
dc.titleIloprost reduces myocardial edema in a rat model of myocardial ischemia reperfusionen_US
dc.titleIloprost reduces myocardial edema in a rat model of myocardial ischemia reperfusion
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu